What happened with PNTG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
The Pennant Group’s agencies send nurses and therapists to patients’ homes and provide clinical care and support for terminally ill patients and their families. Home health and hospice generate most of its revenue. Medicare, the federal health insurance program for older people and eligible people with disabilities, is its largest payer and supplies most hospice revenue. Medicare pays for home health by periods of eligible care and for hospice by daily rates tied to the level of care; managed-care insurers, Medicaid and patients also pay for services.
Pennant also operates senior living communities offering housing, meals and daily assistance, including memory care. This smaller business earns most of its revenue from residents paying directly, with Medicaid and some state programs supplying the rest. Residents generally pay monthly fees based on the services provided and local market conditions.
The care business depends on referrals from physicians, hospitals and other providers, and on government coverage rules and reimbursement rates. Its operations need state licenses and applicable Medicare or Medicaid approvals; expansion and acquisitions also require regulatory approvals. Medicare caps hospice payments and requires providers to repay amounts above the applicable cap.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Chemed’s VITAS competes with Pennant for terminally ill patients and hospice referrals, making its hospice business—not its Roto-Rooter plumbing business—the part to watch. Pennant earned $317.801 million from hospice in 2025, so VITAS’s results speak to a substantial Pennant revenue line.
Addus HomeCare and Pennant compete to provide home nursing, hospice and daily-living assistance to elderly or chronically ill patients, with government programs and managed-care plans paying for care. Watch Addus’s news on payments from those payors: both companies depend on them for home-based care revenue.
Aveanna Healthcare competes with Pennant for home health and hospice patients and referrals, but private duty services dominate Aveanna’s revenue. Its home health admissions and revenue per completed Medicare episode are more relevant to Pennant than Aveanna’s overall growth.
National Healthcare Corp. competes with Pennant in homecare, hospice and senior housing with or without daily-living assistance, although skilled nursing is a larger part of NHC’s business. Its homecare, hospice and senior-living results are therefore the closer comparison for Pennant, whose senior-living revenue comes mainly from residents paying privately.
Ensign’s skilled nursing facilities and Pennant’s home health and senior-living operations share exposure to older patients’ post-acute care needs, government payments and caregiver availability. Watch Ensign’s Medicaid and Medicare payment news for skilled nursing: those programs also materially affect Pennant’s revenue and results, though its senior-living residents mainly pay privately.
UnitedHealth Group’s Optum home health and hospice businesses compete with Pennant for patients receiving care at home. These services are only a small part of UnitedHealth’s overall business, so news about them is more relevant to Pennant than UnitedHealth’s company-wide results.
Housing Starts (Sep)
Pennant’s senior living communities rely partly on seniors’ home-sale proceeds to fund assisted-living fees, so housing activity matters because it can affect residents’ ability to pay and the company’s occupancy and revenue.
Expected1.31MLast release1.275M
If it comes in above expectations
If the reading is above the 1.31M estimate, it is above the previous 1.275M. More home starts or permits point to stronger building activity, but do not by themselves show that seniors are selling homes or receiving proceeds; watch whether home sales and residents’ ability to pay improve to support occupancy and fees.
If it comes in below expectations
Fewer homes started or permitted point to weaker building activity, but do not by themselves establish a decline in home sales; if housing transactions and sale proceeds also weaken, seniors may find fees harder to afford, pressuring occupancy and revenue.
Chemed Corporation earningsCHE
Chemed's VITAS hospice business competes with Pennant for patients and referrals, so its report will show how demand is developing in a market both companies serve.
Focus on patient activity and revenue in VITAS's hospice business. Stronger activity with revenue keeping pace would suggest demand and referrals in this market are holding up; weaker activity would point to more pressure to attract patients and referrals, in a market that supplies a substantial part of Pennant's revenue. The takeaway is whether VITAS's results point to a supportive or more difficult hospice market for Pennant.
Fed Interest Rate Decision
Pennant’s assisted-living business depends partly on seniors using proceeds from home sales to pay fees, so interest rates matter because they affect housing activity and residents’ ability to pay for housing and care.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates may make home sales and residents’ access to sale proceeds weaker, putting pressure on assisted-living occupancy and fee revenue.
If it comes in below expectations
Lower rates may support home sales and residents’ access to sale proceeds, helping them afford fees and supporting assisted-living occupancy and revenue.
Addus HomeCare Corp. earningsADUS
Addus and Pennant both rely on government programs and managed-care plans to pay for home-based care, so Addus's report will show how those payors are treating the services both companies provide.
Watch what Addus says about payments, rates or approvals from government programs and managed-care plans. Stable or improving terms would suggest funding for home-based care is holding up; lower rates, tighter approvals or delayed payments would put more pressure on Pennant's related home-based revenue and operating costs. The conclusion is whether the payors both companies rely on are supporting or squeezing Pennant's home-based care business.
The Pennant Group, Inc. earningsThis company
Pennant's report will show whether growth in home health, hospice and senior living is translating into stronger operating returns.
Read activity alongside revenue per unit: home health admissions and average Medicare revenue per completed 60-day episode, hospice patient census and revenue per day, and senior-living occupancy and monthly revenue per occupied unit. Then compare that growth with the cost of services. Rising activity and revenue without faster cost growth would show that patients and residents are supporting stronger operations; weaker occupancy or patient volume, or costs rising faster than revenue, would make growth harder to convert into operating returns. The conclusion is whether Pennant's expansion is improving the performance of the services it provides.
Aveanna Healthcare Holdings Inc. earningsAVAH
Aveanna competes with Pennant for home health patients and referrals, so its admissions and Medicare revenue per episode will show how demand and payment are developing in a market both companies serve.
Compare Aveanna's home health admissions with average Medicare revenue per completed episode: admissions show patient volume, while revenue per episode shows what each episode brings in. Rising admissions with revenue per episode holding up would suggest both demand and payment are supporting the business; falling admissions with a steady rate would point more to weaker volume, while a falling rate would add pressure on revenue per patient. The takeaway is whether Pennant's home health business faces weaker demand, pressure on revenue per episode, or support on both fronts.
